We spoke to Dr Jack Regan, CEO of LexaGene, a biotechnology company developing a fully automated pathogen detection platform, and inventor of their patented microfluidic system, about the foundations and evolution of the system, and the future outlook for the tool.Read More
We recently spoke to Alif Saleh, CEO of Scipher Medicine to learn how RNA data from a patient’s blood sample can be used to determine the underlying molecular processes driving a disease, and establish how well a patient will respond to a particular therapy.Read More
Microfluidic platforms are becoming commonplace across biological science. To find out more about how microfluidic technology is revolutionizing protein analysis, we spoke to Tuomas Knowles, Founder and Chief Scientific Officer, Fluidic Analytics.
Cities often don't work very well. Bins don't get collected. Traffic queues are long. Shops run out of goods. The Russian team behind Airalab think that AI can help streamline cities and the economy more widely. Their Robonomics platform aims to make it easier to bring automated, intelligent technology into the economy. With Smart City projects already on the go, from Dubai to Milton Keynes, we spoke to Airalab's Aleksandr Kapitonov to find out more.
How can meat processors and retailers assure their customers that the meat they are buying is what is declared on the packaging? A genetic fingerprinting system is now on hand to provide definitive, traceable evidence.Read More
What do biomarkers and a 1990s TGIF party have in common? Find out here...
TBIcheck is a rapid point-of-care diagnostic device that detects biomarkers indicative of mild traumatic brain injury. To find out more, we spoke with the head of the Biomedical Proteomics Group, Jean-Charles Sanchez.
Assay sensitivity and specificity continues to be a challenge in measuring hormones at low concentrations. Tandem mass spectrometry offers significant advantages - particularly in a clinical setting, where speed and sensitivity are required. Following SCIEX' launch of a new tandem mass spectrometry system, we spoke with Michael Jarvis, Product Manager at SCIEX, to find out more.Read More
We recently spoke to Karoly Nikolich, chairman and chief executive officer of Alkahest, a clinical-stage biotechnology company, to learn more about their approach to developing therapeutics for both neurodegenerative and age-related diseases.Read More
OmniTier Inc.’s new bioinformatics platform, CompStorTM Novos, takes a de novo assembly-based variant calling approach to the challenge of whole genome sequencing. We caught up with Jon Coker, Omnitier’s CTO, to discuss how this approach matches up to rival techniques, and how high-performance computing approaches like Omnitier’s hope to bring personalized medicine a step closer and boost biology in coming years.Read More
While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.Read More